市場調査レポート
商品コード
1519789
ニードルフリードラッグデリバリー技術市場:製品、用途、エンドユーザー、地域別、2024年~2032年Needle-free Drug Delivery Technology Market by Product, Application, End User, and Region 2024-2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
ニードルフリードラッグデリバリー技術市場:製品、用途、エンドユーザー、地域別、2024年~2032年 |
出版日: 2024年07月01日
発行: IMARC
ページ情報: 英文 138 Pages
納期: 2~3営業日
|
世界のニードルフリードラッグデリバリー技術の市場規模は2023年に44億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに67億米ドルに達し、2024年から2032年の間に4.56%の成長率(CAGR)を示すと予測しています。慢性疾患の蔓延、高齢人口の増加、レーザーによる無針注射技術(NFIT)の最近の開発は、市場を牽引する主な要因の一つです。
ニードルフリードラッグデリバリー技術とは、従来の注射針を使わずに患者に薬剤を投与する方法を指します。これには、マイクロノズル・ジェット・インジェクター、経皮パッチ、吸入器、使い捨てカートリッジ・インジェクター、点鼻スプレー、超音波などが含まれます。これらは予防接種、インスリン投与、疼痛管理、ホルモン療法、アレルギー、がん、呼吸器疾患、その他の慢性疾患の治療に広く使われています。従来の針を使用したデリバリーシステムと比較して、ニードルフリードラッグデリバリー技術は痛みを軽減し、不快感や不安を最小限に抑え、利便性を高め、患者のコンプライアンスを向上させ、投与量のカスタマイズを可能にし、怪我や感染のリスクを防止します。また、より迅速なドラッグデリバリーを実現し、薬剤の吸収を促進し、合併症を最小限に抑え、治療効果を高めます。ニードルフリーのドラッグデリバリー技術は、有害廃棄物の発生を最小限に抑え、製造時の排出を削減し、製品の廃棄の必要性をなくすため、環境にも優しいです。
糖尿病、がん、クローン病、多発性硬化症、関節炎、骨粗鬆症、心血管疾患(CVDs)などの慢性疾患の有病率の上昇は、市場成長を促進する主な要因の1つです。ニードルフリードラッグデリバリー技術は、痛みや不快感を伴わずに慢性疾患患者にインスリンや薬剤を送達するために広く使用されており、これにより治療成績が向上し、感染症のリスクが低減し、患者のQOLが向上します。さらに、服薬アドヒアランスの向上、薬物吸収の増加、治療効果の向上、注射針に伴う合併症の最小化を目的とした技術の普及が、もう一つの成長促進要因として作用しています。さらに、最近のレーザーを利用したニードルフリー注射技術(NFIT)の動向は、皮膚に薬剤の微細なジェットを高精度で噴射するもので、市場の成長にプラスの影響を与えています。さらに、人道的でストレスのない方法で動物にワクチン、薬、麻酔を投与するための動物医療における技術利用の増加が、市場成長に好影響を与えています。これとは別に、ニードルフリードラッグデリバリーシステムの採用を促進し、先進技術開発を支援するための様々な政府イニシアチブの実施は、市場成長に明るい見通しを生み出しています。その他の要因としては、感染症の流行によるワクチン需要の増加、老人人口の増加、ヘルスケア産業の著しい成長、広範な研究開発活動、ニードルフリードラッグデリバリー技術の利点に関する消費者の意識の高まりなどが挙げられ、市場成長の原動力になると予想されます。
The global needle-free drug delivery technology market size reached US$ 4.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.7 Billion by 2032, exhibiting a growth rate (CAGR) of 4.56% during 2024-2032. The escalating prevalence of chronic diseases, the increasing geriatric population, and the recent development of laser-powered needle-free injection technology (NFIT) represent some of the key factors driving the market.
Needle-free drug delivery technology refers to a method of administering medications to patients without using traditional needles. It includes micronozzle jet injectors, transdermal patches, inhalers, disposable cartridge injectors, nasal sprays, and ultrasound waves. They are widely used for vaccinations, insulin delivery, pain management, hormone therapy, and treating allergies, cancer, respiratory conditions, and other chronic diseases. As compared to traditional needle-based delivery systems, needle-free drug delivery technology reduces pain, minimizes discomfort and anxiety, enhances convenience, improves patient compliance, allows dosage customization, and prevents the risk of injuries and infections. It also offers faster medication delivery and aids in enhancing drug absorption, minimizing complications, and increasing treatment effectiveness. Needle-free drug delivery technology is also eco-friendly as it minimizes hazardous waste generation, reduces manufacturing emissions, and eliminates the need for product disposal.
The escalating prevalence of chronic diseases, such as diabetes, cancer, Crohn's disease, multiple sclerosis, arthritis, osteoporosis, and cardiovascular diseases (CVDs), is one of the primary factors driving the market growth. Needle-free drug delivery technology is widely used to deliver insulin and medications to chronic disease patients without pain and discomfort, which improves treatment outcomes, reduces the risk of infections, and enhances patients' quality of life. Furthermore, the widespread technology adoption to improve medication adherence, increase drug absorption, enhance treatment effectiveness, and minimize complications associated with needles is acting as another growth-inducing factor. Additionally, the recent development of a laser-powered needle-free injection technology (NFIT), which utilizes a laser-based system to blast microscopic jets of drugs into the skin with high precision, is positively influencing the market growth. Moreover, increasing technology utilization in veterinary care to administer vaccines, medications, and anesthesia to animals in a humane and stress-free manner is favoring the market growth. Apart from this, the implementation of various government initiatives to promote the adoption of needle-free drug delivery systems and support the development of advanced technologies are creating a positive outlook for the market growth. Other factors, including rising demand for vaccines due to the increasing prevalence of infectious diseases, increasing geriatric population, significant growth in the healthcare industry, extensive research and development (R&D) activities, and growing consumer awareness regarding the benefits of needle-free drug delivery technology, are anticipated to drive the market growth.
IMARC Group provides an analysis of the key trends in each segment of the global needle-free drug delivery technology market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on product, application, and end user.
Inhaler
Jet Injector
Novel Needles
Transdermal Patch
Others
The report has provided a detailed breakup and analysis of the needle-free drug delivery technology market based on the product. This includes inhaler, jet injector, novel needles, transdermal patch, and others.
Vaccine Delivery
Pain Management
Insulin Delivery
Others
A detailed breakup and analysis of the needle-free drug delivery technology market based on the application has also been provided in the report. This includes vaccine delivery, pain management, insulin delivery, and others.
Hospitals and Clinics
Homecare Settings
Research Laboratories
Academics
Others
A detailed breakup and analysis of the needle-free drug delivery technology market based on the end user has also been provided in the report. This includes hospitals and clinics, homecare settings, research laboratories, academics, and others.
North America
United States
Canada
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for needle-free drug delivery technology. Some of the factors driving the North America needle-free drug delivery technology market included the increasing prevalence of chronic diseases, the implementation of various government initiatives, and rapid technological advancements.
The report has also provided a comprehensive analysis of the competitive landscape in the global needle-free drug delivery technology market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Akra Dermojet, Antares Pharma Inc. (Halozyme Therapeutics Inc.), Crossject, Mika Medical Co., PharmaJet, Portal Instruments Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.